# Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

> **NCT07675057** · — · AVAILABLE · sponsor: **Eli Lilly and Company**

## Conditions studied

- Urinary Bladder Neoplasms
- Neoplasm Metastasis
- Carcinoma, Transitional Cell

## Interventions

- **DRUG:** Vepugratinib

## Key facts

- **NCT ID:** NCT07675057
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07675057

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07675057, "Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07675057. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*